GOLM1 and hepatocellular carcinoma: In the present study, 67.7–70.8% of patients with early HCC who had a negative AFP could be diagnosed by Egfl7, which was slightly better than AFP-L3 (50%) [54], GP73 (66–67%) [16, 54] and comparable with DKK1 (67.3–73.1%) [24, 25].